Key takeaways Thermo Fisher Scientific partners with OpenAI to embed AI across drug development operations. Initial focus on PPD clinical research business aims to reduce clinical trial cycle times. C...
Thermo Fisher Scientific Inc., a global leader in life sciences with over $40 billion in annual revenue, announced on October 16, 2025, a major collaboration with OpenAI to integrate artificial intelligence across its pharmaceutical and clinical research operations.
The partnership aims to reduce the time and cost required to bring new medicines to market while improving the success rate of drug development programs.
The collaboration centers on embedding OpenAI's application programming interfaces into critical business areas including product development, service delivery, customer engagement, and operational workflows.
The initial deployment will focus on Thermo Fisher's PPD clinical research business, one of the company's highest-impact divisions, where AI technology is expected to significantly reduce clinical trial cycle times.
"AI is shaping the future of science. And when combined with our Mission to enable our customers to make the world healthier, cleaner and safer, it is a powerful catalyst to accelerate scientific advancement," said Marc Casper, Chairman, President, and Chief Executive Officer at Thermo Fisher Scientific. "With OpenAI, we're further embedding AI across our operations, products and services. Together, we're building an ecosystem that accelerates scientific breakthroughs and delivers impact for customers, patients and society."
A key component of the partnership involves leveraging AI to identify therapies unlikely to succeed earlier in the development process.
This capability will enable pharmaceutical companies to redirect investment and resources toward more promising drug candidates, potentially saving millions in research costs and years of development time.
The technology will be integrated into Thermo Fisher's Accelerator Drug Development solution, an end-to-end framework spanning early development, Phase I-III clinical research, clinical manufacturing and supply, and commercialization.
The enhanced platform is designed to deliver greater speed, simplicity, and scalability for pharmaceutical customers navigating the complex drug development pipeline.
As part of the broader AI adoption strategy, Thermo Fisher is deploying ChatGPT Enterprise to its global workforce.
The rollout aims to build confidence and fluency with AI tools among employees across departments, supporting the company's goal of embedding artificial intelligence throughout its operations.
Brad Lightcap, Chief Operating Officer at OpenAI, emphasized the potential impact of the collaboration. "Thermo Fisher plays a massive role in advancing science, and together we have an opportunity to accelerate how medicine can reach more people," Lightcap said. "With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients' lives."
The announcement comes as pharmaceutical and biotechnology companies increasingly turn to artificial intelligence to address the rising costs and lengthy timelines associated with drug development.
Key takeaways OpenAI has signed a multi-year, $10 billion agreement with AI chipmaker Cerebras Systems to secure computing infrastructure. The deal will deliver 750 megawatts of computing power throug...
KEY TAKEAWAYS: xAI implemented restrictions preventing Grok from editing images of real people in revealing clothing after global backlash California Attorney General Rob Bonta launched investigation...
Key takeaways TSMC reported fourth-quarter net income of NT$505.74 billion, beating analyst expectations and setting a new record. Fourth-quarter revenue reached NT$1.046 trillion, up 20.5% year over...
